Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28095742 | 0.86 | CYP1A2 (0.48) | CYP1A2SHBGNOS1NOS2 | |
| SCHEMBL2734204 | 0.79 | SHBG (0.35) | CYP1A2SHBG | |
| SCHEMBL15914614 | 0.77 | CYP1A2 (0.37) | CYP1A2SHBGNOS3NOS1NOS2 | |
| SCHEMBL15914307 | 0.77 | CYP1A2 (0.37) | CYP1A2SHBGNOS3NOS1NOS2 | |
| SCHEMBL29012920 | 0.74 | CPN1 (0.31) | — | |
| SCHEMBL15915178 | 0.74 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL15914519 | 0.74 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL28191679 | 0.72 | SIGMAR1 (0.34) | — | |
| SCHEMBL15916141 | 0.71 | CYP1A2 (0.33) | CYP1A2SHBG | |
| SCHEMBL16707886 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | ENDOCYTE INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-9662402-B2 | Drug delivery conjugates containing unnatural amino acids and methods for using | ENDOCYTE, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9555139-B2 | Binding ligand linked drug delivery conjugates of tubulysins | ENDOCYTE, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555139-B2 | Binding ligand linked drug delivery conjugates of tubulysins | ENDOCYTE, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP1A2 4799/4885SHBG 9/4885NOS3 4869/4885 |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | CYP1A2 4475/4885SHBG 4141/4885NOS3 2553/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | CYP1A2 1392/4885SHBG 296/4885NOS3 4815/4885 |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP1A2 4850/4885SHBG 24/4885NOS3 4856/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | CYP1A2 2112/4885SHBG 298/4885NOS3 4876/4885 |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | CYP1A2 2973/4885SHBG 2068/4885NOS3 3516/4885 |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | CD44, HAVCR2, HCAR1 | CYP1A2 4614/4885SHBG 1143/4885NOS3 4860/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | CYP1A2 1292/4885SHBG 338/4885NOS3 4815/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP1A2 4453/4885SHBG 194/4885NOS3 4113/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP1A2 4453/4885SHBG 194/4885NOS3 4113/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP1A2 4799/4885SHBG 9/4885NOS3 4869/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | CYP1A2 4857/4885SHBG 489/4885NOS3 4870/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | CYP1A2 4614/4885SHBG 1143/4885NOS3 4860/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP1A2 4799/4885SHBG 9/4885NOS3 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.